Loading investment pitches...
Equity Research Database
Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Rebounded strongly as bioprocessing destocking bottomed out and order trends stabilized. It represents a...
— Derek Johnston
Full equity research memos, financial breakdowns, and hedge fund thesis write-ups are reserved for BSD Research ($50/mo) and Pro subscribers.
Already a Research or Pro subscriber? Sign In
Other investors who've written on Repligen Corporation
Repligen Corporation is positioned to benefit from numerous company-specific tailwinds in 2025, making it a compelling investment in the bioprocessing space. Despite...
Repligen Corporation recently announced a strategic acquisition of BioLife Solutions to expand its capabilities in the cell therapy market. The deal, valued...